IL17AReceptor抗体;IL17AReceptor Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of IL17A Receptor expression in Raji cell lysate.    

  
  

The IL-17A receptor (IL-17RA) is a key component of the IL-17 signaling pathway, which plays a central role in mediating inflammatory and autoimmune responses. As a type I transmembrane protein, IL-17RA pairs with IL-17RC to form a functional receptor complex that binds IL-17A and IL-17F cytokines. Upon activation, it triggers downstream pro-inflammatory pathways, including NF-κB and MAPK, driving the production of cytokines, chemokines, and antimicrobial peptides. Dysregulation of IL-17 signaling is implicated in chronic inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.

IL-17RA-targeted antibodies, such as brodalumab, are biologic therapies designed to block IL-17-mediated signaling by binding to the receptor and preventing cytokine-receptor interaction. This inhibition reduces inflammatory cascades, offering therapeutic benefits in IL-17-driven conditions. Brodalumab, a fully human monoclonal antibody, has demonstrated efficacy in phase III trials for moderate-to-severe plaque psoriasis, showing rapid and sustained skin clearance. However, targeting IL-17RA may carry risks, including increased susceptibility to infections like mucocutaneous candidiasis, reflecting the receptor's role in mucosal immunity.

Research continues to explore IL-17RA antibodies in broader autoimmune indications, with ongoing studies assessing their potential in diseases like asthma and inflammatory bowel disease. These therapies represent a precision medicine approach to modulating hyperactive immune pathways while balancing efficacy and safety profiles.